Mylin Biotech Pvt Ltd

Scripting Innovation for
Active Health...

Our History

The Idea To Innovate & Care

Inception of Mylin Biotech.
Started operations in Bangalore, India.

First Product Launch

Nitrophage Forte™ launched, for the management
of Uremic pruritis associated with CKD1.
Nitrophage™ launched for the management of MHE2.
Bangalore office established.

FIRST SYNBIOTIC IN INDIA

Niftyy trial published in IJBCP (First ever clinical trial established the
role of synbiotics in management of inflammatory markers)

AMINASE & ENZOBIOTICS CT5

Aminase™ pre-clinical studies completed
Aminase™ clinical trial completed in southern command and published
Launch of Aminase
Enzobiotics pre-clinical studies completed

ENTRY IN CRITICAL CARE

Protinace-98™ launched
Patent applied for Aminase™
Enzobiotics-EETOX clinical trail initiated in ESRD patients
EETOX globally the largest study on PBUT's

PUBLICATIONS & PATENTS

Enzotein™ clinical trial published in International Journal of Nephrology & Therapeutics
First Indian trial presented in American Society of Nephrology conference, Washington
Patent filed for Enzotein and Enzobiotic

MYLIN 2021

Enzobiotic pre-clinical study published
Enzobiotic clinical trial due for publication

GLOBAL MARKET PENETRATION

MYLIN 2021

Enzobiotic pre-clinical study published.
Enzobiotic clinical trial due for publication.

PUBLICATIONS & PATENTS

Enzotein™ clinical trial published in International Journal of Nephrology & Therapeutics.
First Indian trial presented in American Society of Nephrology conference, Washington.
Patent filed for Enzotein and Enzobiotic.

ENTRY IN CRITICAL CARE

Protinace 98™ launched.
Patent applied for Aminase™.
Enzobiotics™ clinical trial initiated in 5 major centers in India.

AMINASE & ENZOBIOTICS Clinical Trial

Aminase™ pre-clinical studies completed
Aminase™ clinical trial completed in southern command and published
Launch of Aminase
Enzobiotics pre-clinical studies completed

FIRST SYNBIOTIC IN INDIA

Niftyy trial published in IJBCP (First ever clinical trial established the
role of synbiotics in management of inflammatory markers).

First Product Launch

Nitrophage Forte™ launched, for the management
of Uremic pruritis associated with Chronic Kidney Disease.
Nitrophage™ launched for the management of Minimal Hepatic Encephalopathy.
Bangalore office established.